Photoactivated HPPH-Liposomal therapy for the treatment of HPV-Negative head and neck cancer.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
09 2023
Historique:
received: 06 04 2023
revised: 31 05 2023
accepted: 29 06 2023
pmc-release: 01 09 2024
medline: 18 7 2023
pubmed: 10 7 2023
entrez: 9 7 2023
Statut: ppublish

Résumé

Human Papillomavirus (HPV)-negative head and neck cancer (HNC) is an aggressive malignancy with a poor prognosis. To improve outcomes, we developed a novel liposomal targeting system embedded with 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH), a chlorin-based photosensitizer. Upon exposure to 660 nm light, HPPH phototriggering generates reactive oxygen species. The objective of this study was to evaluate biodistribution and test efficacy of HPPH-liposomal therapy in a patient-derived xenograft (PDX) model of chemoradioresistant HNC. PDX models were developed from two surgically resected HNCs (P033 and P038) recurrent after chemoradiation. HPPH-liposomes were created including trace amounts of DiR (Ex/Em 785/830 nm), a near infrared lipid probe. Liposomes were injected via tail vein into PDX models. Biodistribution was assessed at serial timepoints in tumor and end-organs through in vivo DiR fluorescence. To evaluate efficacy, tumors were treated with a cw-diode 660 nm laser (90 mW/cm HPPH-liposomes delivered via tail vein exhibited selective tumor penetration, with a peak concentration at 4 h. No systemic toxicity was observed. Treatment with combined HPPH-liposomes and laser resulted in improved tumor control relative to either vehicle or laser alone. Histologically, this manifested as both increased cellular necrosis and decreased Ki-67 staining in the tumors treated with combined therapy. These data demonstrate tumor-specific anti-neoplastic efficacy of HPPH-liposomal treatment for HNC. Importantly, this platform can be leveraged in future studies for targeted delivery of immunotherapies which can be packaged within HPPH-liposomes.

Identifiants

pubmed: 37423200
pii: S1368-8375(23)00183-5
doi: 10.1016/j.oraloncology.2023.106487
pmc: PMC10413333
mid: NIHMS1917070
pii:
doi:

Substances chimiques

2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 149402-51-7
Liposomes 0
Photosensitizing Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106487

Subventions

Organisme : NCI NIH HHS
ID : R01 CA193343
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA279935
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001436
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Oral Oncol. 2018 Jan;76:1-7
pubmed: 29290280
Ann Oncol. 2023 Jan;34(1):101-110
pubmed: 36522816
Anticancer Res. 2008 Nov-Dec;28(6B):3961-4
pubmed: 19192656
Adv Sci (Weinh). 2021 Apr 08;8(10):2002927
pubmed: 34026433
Clin Cancer Res. 2013 Dec 1;19(23):6605-13
pubmed: 24088736
J Immunother. 2010 Sep;33(7):697-705
pubmed: 20664357
Eur J Cancer. 2010 Nov;46(16):3016-21
pubmed: 20801016
Anticancer Res. 2005 Jul-Aug;25(4):3031-9
pubmed: 16080562
Cancer Chemother Pharmacol. 2006 Jan;57(1):40-5
pubmed: 16001178
Ann Oncol. 2010 Nov;21(11):2227-2232
pubmed: 20439345
Theranostics. 2018 Apr 18;8(11):2939-2953
pubmed: 29896295
JCI Insight. 2022 Mar 8;7(5):
pubmed: 35260537
Front Oncol. 2021 Sep 06;11:727433
pubmed: 34552878
Blood. 1997 Oct 1;90(7):2541-8
pubmed: 9326219
Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1002-1011
pubmed: 28721881
J Clin Oncol. 2007 Mar 10;25(8):978-86
pubmed: 17350947
J Control Release. 2018 Jul 28;282:35-45
pubmed: 29673642
Exp Biol Med (Maywood). 2011 Jul;236(7):808-15
pubmed: 21685237
Medicine (Baltimore). 2018 Nov;97(46):e13169
pubmed: 30431590
Lancet Oncol. 2021 Apr;22(4):450-462
pubmed: 33794205
Int J Nanomedicine. 2014 Dec 19;10:125-45
pubmed: 25565809
Cancer Chemother Pharmacol. 2004 Apr;53(4):329-36
pubmed: 14673619
Nat Commun. 2013;4:2126
pubmed: 23839242
Expert Opin Drug Deliv. 2015 Jan;12(1):53-64
pubmed: 25425260
JAMA Otolaryngol Head Neck Surg. 2013 Jul;139(7):706-11
pubmed: 23868427
J Control Release. 2017 Mar 10;249:63-73
pubmed: 28122204
Clin Cancer Res. 2018 Jan 1;24(1):73-83
pubmed: 29018051
J Biophotonics. 2016 Dec;9(11-12):1344-1354
pubmed: 27653233
Adv Drug Deliv Rev. 2013 Jan;65(1):71-9
pubmed: 23088862
Cytokine Growth Factor Rev. 2002 Apr;13(2):155-68
pubmed: 11900991
Int J Nanomedicine. 2020 Jan 10;15:137-149
pubmed: 32021170

Auteurs

Joseph Zenga (J)

Department of Otolaryngology, Medical College of Wisconsin, Milwaukee, WI, USA.

Musaddiq Awan (M)

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

Mir Hadi Razeghi Kondelaji (M)

Joint Department of Biomedical Engineering, Marquette University/Medical College of Wisconsin, Milwaukee, WI, USA.

Christopher Hansen (C)

Joint Department of Biomedical Engineering, Marquette University/Medical College of Wisconsin, Milwaukee, WI, USA.

Shayan Shafiee (S)

Joint Department of Biomedical Engineering, Marquette University/Medical College of Wisconsin, Milwaukee, WI, USA.

Anne Frei (A)

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

Jamie Foeckler (J)

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

Rachel Kuehn (R)

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

Jennifer Bruening (J)

Department of Otolaryngology, Medical College of Wisconsin, Milwaukee, WI, USA.

Becky Massey (B)

Department of Otolaryngology, Medical College of Wisconsin, Milwaukee, WI, USA.

Stuart Wong (S)

Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Amit Joshi (A)

Joint Department of Biomedical Engineering, Marquette University/Medical College of Wisconsin, Milwaukee, WI, USA.

Heather A Himburg (HA)

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address: hhimburg@mcw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH